Demographics, Pattern of Care & Outcomes of Primary CNS Lymphoma- Experience from a Tertiary Care Cancer Center in India

Lenalidomide following whole‐brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy

“…1 Despite intensive high-dose methotrexate-based induction and consolidation, a significant proportion of patients are primarily refractory and progress during therapy. 2 Prognosis of patients with relapsed/refractory disease is even poorer with progression-free survival (PFS) and overall survival (OS) of 2.2 and 3.5 months respectively in real-world settings. 3 In a relapse setting systemic therapy with agents such as temozolomide, temsirolimus, ibrutinib and lenalidomide has overall response rates (ORRs) of 31%-67% and a short median PFS of 1.9-7.8 months.…”

“…Bhausaheb Bagal 1,2 Rup Sarma 1 Sayak Dey 1 Lingaraj Nayak 1,2 Avinash Bonda 1,2 Jayant Goda 1,3 Nehal Khanna 1,3 Archya Dasgupta 1,3 Sangeeta Kakoti 1,3 Abhishek Chatarjee 1,3 Hasmukh Jain 1,2 Sridhar Epari 1,4 Siddhartha Laskar 1,3 Manju Sengar 1,2 Tejpal Gupta…”